

091-135302

For Internal Use Only  
Sec File No. 9-

RECEIVED  
2011 NOV 15 PM 4:25  
SEC / MB

Submit 1 Original  
and 9 Copies

OMB APPROVAL  
OMB Number: 3235-0504  
Expires: July 31, 2001  
Estimated average burden  
hours per response..... 2.00

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 19b-4(e)

Information Required of a Self-Regulatory Organization Listing and Trading a New  
Derivative Securities Product Pursuant to Rule 19b-4(e) Under the Securities Exchange Act of 1934

READ ALL INSTRUCTIONS PRIOR TO COMPLETING FORM



11032890

Part I

Initial Listing Report

- Name of Self-Regulatory Organization Listing New Derivative Securities Product:  
Chicago Stock Exchange
- Type of Issuer of New Derivative Securities Product (e.g., clearinghouse, broker-dealer, corporation, etc.):  
bank
- Class of New Derivative Securities Product:  
index to track performance of equity secs. involved in pharmaceuticals
- Name of Underlying Instrument:  
RBS Global Big Pharma ETN
- If Underlying Instrument is an Index, State Whether it is Broad-Based or Narrow-Based:  
narrow based
- Ticker Symbol(s) of New Derivative Securities Product:  
DRGS
- Market or Markets Upon Which Securities Comprising Underlying Instrument Trades:  
various
- Settlement Methodology of New Derivative Securities Product:  
see Prospectus
- Position Limits of New Derivative Securities Product (if applicable):  
see Prospectus

Part II

Execution

The undersigned represents that the governing body of the above-referenced Self-Regulatory Organization has duly approved, or has duly delegated its approval to the undersigned for, the listing and trading of the above-referenced new derivative securities product according to its relevant trading rules, procedures, surveillance programs and listing standards.

Name of Official Responsible for Form:  
James Ongena

Title:  
Vice President and Associate General Counsel

Telephone Number:  
312 663 2937

Manual Signature of Official Responsible for Form:

Date: 11/11/2011

Act	Securities Exchange Act of 1934
Section	19b-4
Rule	19b-4(e)
Public	
Availability:	NOV 15 2011



RECEIVED

2011 NOV 15 PM 4: 24

SEC / MR

November 14, 2011

**BY U.S. MAIL**

Ms. Galye S. Jackson  
Division of Trading and Markets  
Securities and Exchange Commission  
100 F Street N.E. – Stop 7010  
Washington, D.C. 20549

**Re: Form 19b-4(e) for various ETFs**

Dear Ms. Jackson:

Pursuant to Rule 19b-4(e) of the Securities Exchange Act of 1934, I enclose for filing an original and nine copies of the Forms 19b-4(e) relating to the following ETFs:

- Direxion (CURE, SICK, TOTS, MATL, MATS)
- Market Vectors (XMPT)
- Powershares (SPHB, SPLV, BKLN)
- Claymore (RYJ, FRN)
- E-Tracs (AAVX, BBVX, CCVX, DDVX, EEVX, FFVX, VXAA, VXBB, VXCC, VXDD, VXEE, VXFF, OILZ, GASZ)
- RBS Global (DRGS)
- Velocity Shares (UGLD, DGLD, USLV, DSLV, LPLT, IPLT, LPAL, IPAL)

If you have any questions about this filing, please contact me at (312) 663-2937.

Sincerely,

James Ongena  
Associate General Counsel

Act	Securities Exchange Act of 1934
Section	19b-4
Rule	19b-4(e)
Public Availability:	NOV 15 2011

Enclosures